Compare · BIAF vs IQV
BIAF vs IQV
Side-by-side comparison of bioAffinity Technologies Inc. (BIAF) and IQVIA Holdings Inc. (IQV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIAF and IQV operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- IQV is the larger of the two at $31.18B, about 3960.6x BIAF ($7.9M).
- Over the past year, BIAF is down 78.1% and IQV is up 34.3% - IQV leads by 112.4 points.
- BIAF has been more active in the news (7 items in the past 4 weeks vs 6 for IQV).
- IQV has more recent analyst coverage (25 ratings vs 0 for BIAF).
- Company
- bioAffinity Technologies Inc.
- IQVIA Holdings Inc.
- Price
- $1.74+4.19%
- $186.79+2.51%
- Market cap
- $7.9M
- $31.18B
- 1M return
- -30.40%
- +17.94%
- 1Y return
- -78.08%
- +34.33%
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NYSE
- IPO
- 2022
- 2013
- News (4w)
- 7
- 6
- Recent ratings
- 0
- 25
IQVIA Holdings Inc.
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
Latest BIAF
- bioAffinity Technologies Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- bioAffinity Technologies Announces Notification of Mexico Patent Allowance Covering Novel Lung Cancer Detection Methods Using CyPath® Lung Technology
- SEC Form S-8 filed by bioAffinity Technologies Inc.
- SEC Form 424B3 filed by bioAffinity Technologies Inc.
- SEC Form EFFECT filed by bioAffinity Technologies Inc.
- bioAffinity Technologies Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- bioAffinity Technologies Reports Record Monthly CyPath® Lung Unit Sales and Significant Year-Over-Year Growth in April 2026
- bioAffinity Technologies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- bioAffinity Technologies Reports First Quarter 2026 Results and Expanding Adoption and Clinical Usage of CyPath® Lung
- SEC Form S-1 filed by bioAffinity Technologies Inc.
Latest IQV
- IQVIA CEO to Speak at Jefferies Global Healthcare Conference
- IQVIA and Kexing Biopharm Expand Strategic Collaboration to Accelerate Global Biosimilar Development using AI-Enabled Capabilities
- SEC Form 4 filed by Director Wims Morris Leslie
- SEC Form 4 filed by Director Goggins Colleen A
- SEC Form 4 filed by Director Fasano Jim
- SEC Form 4 filed by Director Danhakl John G
- SEC Form 8-K filed by IQVIA Holdings Inc.
- IQVIA Board of Directors Approves $2 Billion Increase in Share Repurchase Authorization
- IQVIA CFO to Speak at Bank of America Health Care Conference 2026
- SEC Form 10-Q filed by IQVIA Holdings Inc.